Search
Search
John P. Berdahl, MD; Preeya K. Gupta, MD; Nathan M. Radcliffe, MD; Thomas W. Samuelson, MD; I. Paul Singh, MD; Vance Thompson, MD, FACS
Show Description +
Six glaucoma experts sat down to share their insights on the TearClear pipeline, making it possible to deliver Latanoprost safely and effectively without direct patient exposure to benzalkonium chloride (BAK). Watch to learn more about what it offers to patients and practitioners.
Posted: 10/01/2021
John P. Berdahl, MD; Preeya K. Gupta, MD; Nathan M. Radcliffe, MD; Thomas W. Samuelson, MD; I. Paul Singh, MD; Vance Thompson, MD, FACS
Six glaucoma experts sat down to share their insights on the TearClear pipeline, making it possible to deliver Latanoprost safely and effectively without direct patient exposure to benzalkonium chloride (BAK). Watch to learn more about what it offers to patients and practitioners.
Posted: 10/01/2021
About TearClear
TearClear is an ophthalmic pharmaceutical company that transforms trusted drugs into best-in-class therapies. Our novel platform keeps preservatives safely in the bottle enabling preservative-free drops on to the ocular surface.
Visit us online at tearclear.com and connect with us on LinkedIn.
© 2021 TearClear Corp. All rights reserved.
